Marina Basina, Clinical Professor of Medicine- Endocrinology, Gerontology, and Metabolism at Stanford Medicine, said the study showed how the drug can be an alternative help to people when short-acting insulin isnt controlling blood sugar levels
Fast Turnaround Flat-Rate Pricing Free Shipping For Patients For Patients For Providers Frequently Asked Questions Please allow up to 3-7 business days to receive your prescriptions after checkout
GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Others), By Application (Type 2 Diabetes Mellitus, Chronic Weight Management, Cardiovascular Risk Reduction, Others), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034 Last Updated: July 17, 2026 | Author: Pavan Warade | Format: | Report Code: SR8134DR | Pages: 200 GLP-1 Receptor Agonist Market Size & Growth Analysis The GLP-1 receptor agonist market size was valued at USD 56.34 billion in 2025 and is projected to grow from USD 63.24 billion in 2026 to USD 161.40 billion by 2034, registering a CAGR of 12.43% during the forecast period (20262034)
Zepbound single-dose vials are offered via LillyDirect and are available as a cash pay-only offering starting at $299/mo for the 2.5 mg dose
Semaglutide GLP-1, the active ingredient found in various brand-name medications such as Ozempic and Wegovy, is a commercially produced medication
